Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 15, Issue 1, 2017, Pages 9-20

  Daly, Mary B ^a   Pilarski, Robert ^b   Berry, Michael ^c   Buys, Saundra S ^d   Farmer, Meagan ^e   Friedman, Susan ^f   Garber, Judy E ^g   Kauff, Noah D ^h   Khan, Seema ⁱ   Klein, Catherine ^j   Kohlmann, Wendy ^d   Kurian, Allison ^k   Litton, Jennifer K ^l   Madlensky, Lisa ^m   Merajver, Sofia D ⁿ   Offit, Kenneth ^o   Pal, Tuya ^p   Reiser, Gwen ^q   Shannon, Kristen Mahoney ^r   Swisher, Elizabeth ^s   Vinayak, Shaveta ^t   Voian, Nicoleta C ^u   Weitzel, Jeffrey N ^v   Wick, Myra J ^w   Wiesner, Georgia L ^x   Dwyer, Mary ^y   Darlow, Susan ^y   more..

^a FOX CHASE CANCER CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f FORCE Facing Our Risk of Cancer Empowered   (United States)

^g Dana Farber Brigham and Women's Cancer Center   (United States)

^h DUKE CANCER INSTITUTE   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j University of Colorado Cancer Center   (United States)

^k STANFORD CANCER INSTITUTE   (United States)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁿ UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^p H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^q UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^r MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^s UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^t UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^u ROSWELL PARK CANCER INSTITUTE   (United States)

^v CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^w MAYO CLINIC CANCER CENTER   (United States)

^x VANDERBILT INGRAM CANCER CENTER   (United States)

^y National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 INTERACTION PROTEIN C TERMINAL HELICASE 1; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; NEUROFIBROMIN; NIBRIN; PARTNER AND LOCALIZER OF BRCA2 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN P53; RAD51 PROTEIN; RAD51C PROTEIN; RAD51D PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

BREAST CANCER; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GERMLINE MUTATION; HEREDITARY TUMOR; HIGH RISK POPULATION; HUMAN; OVARY CANCER; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; FEMALE; GENETICS; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; MUTATION; RISK FACTOR; STANDARDS;

FEMALE; GENETIC COUNSELING; GENETIC TESTING; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMANS; MUTATION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 85009085880     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2017.0003     Document Type: Review

References (71)

1. Lynch HT, Watson P, Conway TA, Lynch JF. Clinical/genetic features in hereditary breast cancer. Breast Cancer Res Treat 1990;15: 63-71.
2. Pharoah PD, Day NE, Duffy S, et al. Family history and the risk of breast cancer: A systematic review and meta-analysis. Int J Cancer 1997;71: 800-809.
3. Lancaster JM, Powell CB, Chen LM, Richardson DL. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2015;136: 3-7.
4. Shiovitz S, Korde LA. Genetics of breast cancer: A topic in evolution. Ann Oncol 2015;26: 1291-1299.
5. Axilbund JE. Panel testing is not a panacea. J Clin Oncol 2016;34: 1433-1435.
6. Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 2016;13: 581-588.
7. Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 2015;372: 2243-2257.
8. Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol 2016;34: 1460-1468.
9. Broeks A, Urbanus JH, Floore AN, et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet 2000;66: 494-500.
10. Brunet J, Gutierrez-Enriquez S, Torres A, et al. ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations. Clin Genet 2008;73: 465-473.
11. Heikkinen K, Rapakko K, Karppinen SM, et al. Association of common ATM polymorphism with bilateral breast cancer. Int J Cancer 2005;116: 69-72.
12. Tommiska J, Jansen L, Kilpivaara O, et al. ATM variants and cancer risk in breast cancer patients from Southern Finland. BMC Cancer 2006;6: 209.
13. van Os NJ, Roeleveld N, Weemaes CM, et al. Health risks for ataxia-telangiectasia mutated heterozygotes: A systematic review, meta-analysis and evidence-based guideline. Clin Genet 2016;90: 105-117.
14. Goldgar DE, Healey S, Dowty JG, et al. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res 2011;13: R73.
15. Bernstein JL, Haile RW, Stovall M, et al. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst 2010;102: 475-483.
16. Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2015;2: 1-9.
17. Ramus SJ, Song H, Dicks E, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst 2015;107: Pii: Djv214.
18. Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 2011;43: 1104-1107.
19. Fleming GF, Seidman J, Lengyel E. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, eds. Principles and Practice of Gynecologic Oncology, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013: 757-847.
20. Easton DF, Lesueur F, Decker B, et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: Implications for gene panel testing. J Med Genet 2016;53: 298-309.
21. Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007;297: 2360-2372.
22. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001;121: 1348-1353.
23. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006;295: 1379-1388.
24. Apostolou P, Fostira F. Hereditary breast cancer: The era of new susceptibility genes. Biomed Res Int 2013;2013: 747318.
25. Iniesta MD, Gorin MA, Chien LC, et al. Absence of CHEK2∗1100delC mutation in families with hereditary breast cancer in North America. Cancer Genet Cytogenet 2010;202: 136-140.
26. Kuusisto KM, Bebel A, Vihinen M, et al. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res 2011;13: R20.
27. Cybulski C, Wokolorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 2011;29: 3747-3752.
28. Weischer M, Bojesen SE, Ellervik C, et al. CHEK2∗1100delC genotyping for clinical assessment of breast cancer risk: Meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 2008;26: 542-548.
29. Naslund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2∗1100delC heterozygotes estimated from the Copenhagen General Population Study. J Clin Oncol 2016;34: 1208-1216.
30. CHEK2∗1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004;74: 1175-1182.
31. Schmidt MK, Hogervorst F, van Hien R, et al. Age-and tumor subtype-specific breast cancer risk estimates for CHEK2∗1100delC carriers. J Clin Oncol 2016;34: 2750-2760.
32. Han FF, Guo CL, Liu LH. The effect of CHEK2 variant I157T on cancer susceptibility: Evidence from a meta-analysis. DNA Cell Biol 2013;32: 329-335.
33. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305: 2304-2310.
34. Kohlmann W, Gruber S. Lynch Syndrome. In: {agon RA, Adam MP, Ardinger HH, et al, eds. GeneReviews [Internet] Seattle, WA: University of Washington, Seattle; 1993-2016.
35. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systematic review. JAMA 2006;296: 1507-1517.
36. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008;123: 444-449.
37. Chen LM, Yang KY, Little SE, et al. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol 2007;110: 18-25.
38. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354: 261-269.
39. Stuckless S, Green J, Dawson L, et al. Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation. Clin Genet 2013;83: 359-364.
40. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015;110: 223-262; quiz 263.
41. Stoffel EM, Mangu PB, Gruber SB, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol 2015;33: 209-217.
42. ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol 2014;124: 1042-1054.
43. Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand 2011;90: 437-444.
44. Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, et al. Ten years after mutation testing for Lynch syndrome: Cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009;27: 4793-4797.
45. Renkonen-Sinisalo L, Butzow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007;120: 821-824.
46. Rijcken FE, Mourits MJ, Kleibeuker JH, et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003;91: 74-80.
47. Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002;94: 1708-1712.
48. Harkness EF, Barrow E, Newton K, et al. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: A cohort study. J Med Genet 2015;52: 553-556.
49. Bogdanova N, Feshchenko S, Schurmann P, et al. Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int J Cancer 2008;122: 802-806.
50. Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-cancer risk: Comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 2011;12: 477-488.
51. Steffen J, Nowakowska D, Niwinska A, et al. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer 2006;119: 472-475.
52. Zhang G, Zeng Y, Liu Z, Wei W. Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk. Tumour Biol 2013;34: 2753-2757.
53. Uusitalo E, Rantanen M, Kallionpaa RA, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol 2016;34: 1978-1986.
54. Rosenfeld A, Listernick R, Charrow J, Goldman S. Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst 2010;26: 663-667.
55. Nishida T, Tsujimoto M, Takahashi T, et al. Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I. J Gastroenterol 2016;51: 571-578.
56. Walker L, Thompson D, Easton D, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006;95: 233-238.
57. Sharif S, Moran A, Huson SM, et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 2007;44: 481-484.
58. Evans DG. Are we ready for targeted early breast cancer detection strategies in women with NF1 aged 30-49 years? Am J Med Genet A 2012;158a: 3054-3055.
59. Seminog OO, Goldacre MJ. Age-specific risk of breast cancer in women with neurofibromatosis type 1. Br J Cancer 2015;112: 1546-1548.
60. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007;44: 81-88.
61. Thompson ER, Rowley SM, Li N, et al. Panel testing for familial breast cancer: Calibrating the tension between research and clinical care. J Clin Oncol 2016;34: 1455-1459.
62. Casadei S, Norquist BM, Walsh T, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 2011;71: 2222-2229.
63. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015;33: 304-311.
64. Cybulski C, Kluzniak W, Huzarski T, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: A prospective cohort analysis. Lancet Oncol 2015;16: 638-644.
65. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014;371: 497-506.
66. Kanchi KL, Johnson KJ, Lu C, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun 2014;5: 3156.
67. Tischkowitz M, Xia B. PALB2/FANCN: Recombining cancer and Fanconi anemia. Cancer Res 2010;70: 7353-7359.
68. Loveday C, Turnbull C, Ruark E, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 2012;44: 475-476; author reply 476.
69. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011;43: 879-882.
70. Song H, Dicks E, Ramus SJ, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol 2015;33: 2901-2907.
71. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006;12: 3209-3215.